No other company replicates this because the insurance companies only negotiate with the large manufacturers so new startups would not only have to make themselves known to insurance companies but would also have to more than likely financially incentivize the insurance companies to recognize them, which the insurance companies will promptly ignore because the copay on insulin is so monstrously high that it doesn’t make sense for them to stop the deal they have with current manufacturers when they get to charge higher premiums with the current brands
Latest Answers